FDA nod to Boehringer Ingelheim’s first-line therapy for HER2-mutant lung cancer

Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy

Eugia Pharma receives USFDA Approval for Everolimus tablets

Zelluna gets green light for first-in-human trial of groundbreaking TCR-NK cancer therapy

The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers

UK pours £20 million into cutting?edge tech to tackle drug & alcohol addiction

The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences

Ultragenyx bags FDA priority review for groundbreaking GSDIa gene therapy

If approved, DTX401 would be the first treatment to address the disease at its root cause

FDA nod to AstraZeneca’s all-oral, fixed-duration therapy for CLL & SLL

The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years

CARE Hospitals positions workforce health as a strategic business imperative at HR Conclave 2026

200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities

VivaMed BioPharma teams up with Syngene International to fast-track AI-driven drug programmes

The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities

FDA accepts Teva’s NDA for long-acting schizophrenia injection

If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations

FDA greenlights first all-oral, fixed-duration combo therapy for untreated CLL patients

The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy